Retatrutide vs Syn-Ake
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Syn-Ake
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic tripeptide that mimics the effect of Waglerin-1, a peptide found in Temple Viper venom. It's used in cosmetics for anti-wrinkle effects.
Full details →Side-by-Side Comparison
| Aspect | Retatrutide | Syn-Ake |
|---|---|---|
| Mechanism | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. | Acts as a competitive antagonist at the nicotinic acetylcholine receptor, reducing muscle contractions similar to Botox but through a different mechanism. Provides muscle-relaxing effects when applied topically. |
| Typical Dosage | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. | Topical: 1-4% concentration in serums or creams. Applied 1-2 times daily to target areas like forehead and crow's feet. |
| Administration | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. | Topical application only. Should be applied to clean skin. Often combined with other anti-aging peptides for synergistic effects. |
| Side Effects | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. | Generally well-tolerated topically. Rare reports of mild skin irritation or sensitivity. |
| Best For |